Aditya H Gaur
Overview
Explore the profile of Aditya H Gaur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
2022
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moore C, Baltrusaitis K, Best B, Moye J, Townley E, Violari A, et al.
Lancet HIV
. 2025 Mar;
12(3):e191-e200.
PMID: 40049924
Background: Long-acting cabotegravir and long-acting rilpivirine constitute a completely intramuscular antiretroviral therapy (ART) regimen for adults with HIV. We aimed to assess the safety, antiviral activity, and pharmacokinetics of oral...
2.
Heine R, Terry G, Gaur A
J Patient Cent Res Rev
. 2025 Feb;
12(1):32-34.
PMID: 39906606
No abstract available.
3.
Natukunda E, Gaur A, Kosalaraksa P, Hellstrom E, Strehlau R, Liberty A, et al.
J Int AIDS Soc
. 2025 Jan;
28(2):e26414.
PMID: 39888251
Introduction: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was efficacious and well tolerated in children/adolescents with HIV (aged ≥6 years, weighing ≥25 kg) in a Phase 2/3 study. Here, we report data from children...
4.
Carpp L, Hyrien O, Fong Y, Benkeser D, Roels S, Stieh D, et al.
Nat Commun
. 2024 Nov;
15(1):9785.
PMID: 39532861
Assessment of immune correlates of severe COVID-19 has been hampered by the low numbers of severe cases in COVID-19 vaccine efficacy (VE) trials. We assess neutralizing and binding antibody levels...
5.
Rodriguez C, Natukunda E, Strehlau R, Venter E, Rungmaitree S, Cunningham C, et al.
Lancet HIV
. 2024 Apr;
11(5):e300-e308.
PMID: 38621393
Background: Coformulated bictegravir, emtricitabine, and tenofovir alafenamide is a single-tablet regimen and was efficacious and well tolerated in children and adolescents with HIV (aged 6 years to <18 years) in...
6.
Lowenthal E, Chapman J, Ohrenschall R, Calabrese K, Baltrusaitis K, Heckman B, et al.
Lancet HIV
. 2024 Mar;
11(4):e222-e232.
PMID: 38538161
Background: Long-acting injectable cabotegravir and rilpivirine have demonstrated safety, acceptability, and efficacy in adults living with HIV-1. The IMPAACT 2017 study (MOCHA study) was the first to use these injectable...
7.
Gaur A, Capparelli E, Calabrese K, Baltrusaitis K, Marzinke M, McCoig C, et al.
Lancet HIV
. 2024 Mar;
11(4):e211-e221.
PMID: 38538160
Background: Combined intramuscular long-acting cabotegravir and long-acting rilpivirine constitute the first long-acting combination antiretroviral therapy (ART) regimen approved for adults with HIV. The goal of the IMPAACT 2017 study (MOCHA...
8.
9.
Hijano D, Dennis S, Hoffman J, Tang L, Hayden R, Gaur A, et al.
Front Public Health
. 2024 Jan;
11:1304072.
PMID: 38259752
Background: Case investigations and contact tracing are essential disease control measures used by health departments. Early in the pandemic, they were seen as a key strategy to stop COVID-19 spread....
10.
Lindsey J, Hudgens M, Gaur A, Horvath K, Dallas R, Heckman B, et al.
J Acquir Immune Defic Syndr
. 2023 Feb;
92(3):231-241.
PMID: 36730762
Introduction: Youth living with HIV in the US have low rates of viral suppression, in part because of challenges with antiretroviral therapy adherence. Methods: Daily dosing in the Adolescent Medicine...